NCT02954991: A reported trial by Mirati Therapeutics Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02954991 |
|---|---|
| Title | A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Nov. 7, 2016 |
| Completion date | Nov. 4, 2021 |
| Required reporting date | Nov. 4, 2024, midnight |
| Actual reporting date | Jan. 26, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |